HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

High metabolic heterogeneity on baseline (18)FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1182/bloodadvances.2020001816


Title: High metabolic heterogeneity on baseline (18)FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma
Authors: Senjo, Hajime Browse this author
Hirata, Kenji Browse this author →KAKEN DB
Izumiyama, Koh Browse this author
Minauchi, Koichiro Browse this author
Tsukamoto, Eriko Browse this author →KAKEN DB
Itoh, Kazuo Browse this author →KAKEN DB
Kanaya, Minoru Browse this author
Mori, Akio Browse this author
Ota, Shuichi Browse this author
Hashimoto, Daigo Browse this author →KAKEN DB
Teshima, Takanori Browse this author →KAKEN DB
Issue Date: 26-May-2020
Publisher: American Society of Hematology
Journal Title: Blood Advances
Volume: 4
Issue: 10
Start Page: 2286
End Page: 2296
Publisher DOI: 10.1182/bloodadvances.2020001816
Abstract: Metabolic heterogeneity (MH) can be measured using F-18-fluorodeoxyglucose ((18)FDG) positron emission tomography/computed tomography (PET/CT), and it indicates an inhomogeneous tumor microenvironment. High MH has been shown to predict a worse prognosis for primary mediastinal B-cell lymphoma, whereas its prognostic value in diffuse large B-cell lymphoma (DLBCL) remains to be determined. In the current study, we investigated the prognostic values of MH evaluated in newly diagnosed DLBCL. In the training cohort, 86 patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone-like chemotherapies were divided into low-MH and high-MH groups using receiver operating characteristic analysis. MH was not correlated with metabolic tumor volume of the corresponding lesion, indicating that MH was independent of tumor burden. At 5 years, overall survivals were 89.5% vs 61.2% (P = .0122) and event-free survivals were 73.1% vs 51.1% (P = .0327) in the low- and high-MH groups, respectively. A multivariate Cox-regression analysis showed that MH was an independent predictive factor for overall survival. The adverse prognostic impacts of high MH were confirmed in an independent validation cohort with 64 patients. In conclusion, MH on baseline (18)FDG-PET/CT scan predicts treatment outcomes for patients with newly diagnosed DLBCL.
Type: article
URI: http://hdl.handle.net/2115/78746
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University